22,245 results match your criteria Breast Cancer and HER2

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.

Eur J Cancer 2021 Jun 18;153:133-141. Epub 2021 Jun 18.

Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35128 Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.

Aim: The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.

Methods: The Cher-LOB study randomised 121 patients with human epidermal growth factor receptor 2-positive, stage II-IIIA breast cancer. Read More

View Article and Full-Text PDF

Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer.

Cancer Lett 2021 Jun 18;518:82-93. Epub 2021 Jun 18.

Cancer Institute, Dalian Key Laboratory of Molecular Targeted Cancer Therapy, The Second Hospital of Dalian Medical University, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China. Electronic address:

Despite HER2-targeted cancer treatments have provided considerable clinical benefits, resistance to HER2-targeted agents will inevitably develop. Targeting non-oncogene vulnerabilities including endoplasmic reticulum (EnR) stress has emerged as an attractive alternative approach to improve the efficacy of existing targeted cancer therapies. In the current study, we find that Melatonin sensitizes HER2-positive breast cancer cells to the dual tyrosine kinase inhibitor Lapatinib in vitro. Read More

View Article and Full-Text PDF

Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.

Int J Cancer 2021 Jun 21. Epub 2021 Jun 21.

Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Lung adenocarcinoma (LUAD) is the most common types among lung cancers generally arising from terminal airway and understanding of multistep carcinogenesis is crucial to develop novel therapeutic strategy for LUAD. Here we used human induced pluripotent stem cells (hiPSCs) to establish iHER2-hiPSCs in which doxycycline induced the expression of the oncoprotein HER2/ERBB2. Lung progenitors that differentiated from iHER2-hiPSCs, which expressed NKX2-1/TTF-1 known as a lung lineage maker, were cocultured with human fetal fibroblast and formed Human lung organoids (HLOs) comprising alveolar type 2-like cells. Read More

View Article and Full-Text PDF

Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.

Am J Clin Oncol 2021 Jul;44(7):340-349

US HEOR and Real World Evidence Solutions, IQVIA, San Francisco, CA.

Objective: Ado-trastuzumab emtansine (T-DM1) was recently approved for patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC) with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Cost-effectiveness analysis was conducted to compare T-DM1 versus trastuzumab in the United States.

Materials And Methods: A Markov cohort-based model tracked clinical and economic outcomes over a lifetime horizon from a US payer perspective. Read More

View Article and Full-Text PDF

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.

Front Med (Lausanne) 2021 2;8:658747. Epub 2021 Jun 2.

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

This study evaluated the cost-effectiveness of abemaciclib plus fulvestrant (ABE + FUL) vs. palbociclib plus fulvestrant (PAL + FUL), ribociclib plus fulvestrant (RIB + FUL) and fulvestrant monotherapy (FUL) as second-line treatment for hormone receptor-positive and human epidermal growth factor receptor 2- negative advanced or metastatic breast cancer in the US. The 3 health states partitioned survival (PS) model was used over the lifetime. Read More

View Article and Full-Text PDF

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer.

Front Oncol 2021 4;11:689587. Epub 2021 Jun 4.

Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Background: The trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the first real-world comparison of CT-P6 versus RTZ with dual HER2-targeted therapy for the neoadjuvant and palliative first-line treatment with HER2-positive EBC and metastatic breast cancer (MBC) patients in two tertiary hospitals in Korea.

Methods: We retrospectively investigated medical records in the Severance Breast Cancer Registry in Korea. Read More

View Article and Full-Text PDF

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.

Front Oncol 2021 2;11:602222. Epub 2021 Jun 2.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Although positive Circulating tumor cells (CTCs) status has been validated as a prognostic marker in breast cancer, the interaction between immune cells and CTCs during the progress of Epithelial-mesenchymal-transition (EMT), and the clinical implications of CTC-associated white blood cell clusters (CTC-WBC clusters) for metastatic breast cancer are largely uncharacterized.

Methods: We optimized a filter-based method combined with an RNA hybridization technique according to the epithelial- and mesenchymal-markers to analyze EMT in CTC-WBC clusters. Serial peripheral blood samples from 135 patients with Hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving first-line chemotherapy with docetaxel plus capecitabine were prospectively collected until disease progression from Nov 2013 to March 2019. Read More

View Article and Full-Text PDF

Expression status and prognostic value of the perilipin family of genes in breast cancer.

Am J Transl Res 2021 15;13(5):4450-4463. Epub 2021 May 15.

Department of Oncology, Liuzhou People's Hospital Liuzhou 545001, Guangxi Zhuang Autonomous Region, China.

Background: The Perilipin (PLIN) family of genes were previously shown to be involved in the formation and degradation of Lipid Droplets (LDs). In addition, they may play important roles in the development and progression of breast cancer. However, the prognostic value of PLIN family members in breast cancer patients remains unclear. Read More

View Article and Full-Text PDF

Novel Agents for the Management of Endocrine Resistant Breast Cancer.

Curr Breast Cancer Rep 2018 Dec 15;10(4):274-281. Epub 2018 Nov 15.

Division of Hematology/Oncology, Vanderbilt University Medical Center (VUMC)/Vanderbilt-Ingram Cancer Center (VICC), 2220 Pierce Ave. 777 PRB, Nashville, TN 37232, USA.

Purpose Of Review: Most women with hormone receptor (HR)-positive, HER2-negative (HR+/HER2-) breast cancer will ultimately develop endocrine-resistant disease, either primary or acquired. This review will discuss the proposed mechanisms underlying endocrine resistance and key advances in the treatment of endocrine-resistant breast cancer.

Recent Findings: Estrogen receptor 1 mutations () occur in the majority of patients with HR+/HER2- metastatic breast cancer after prolonged exposure to aromatase inhibitors. Read More

View Article and Full-Text PDF
December 2018

Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not.

J Cancer 2021 4;12(15):4722-4728. Epub 2021 Jun 4.

Department of Surgery, Chung-Ang University College of Medicine, 224-1, Heukseok-dong, Dongjak-gu, Seoul 06973, Republic of Korea.

Accurate determination of human epidermal growth factor receptor 2 (HER2) status on breast core needle biopsy (CNB) tissue is important for determining neoadjuvant chemotherapies (NACs) for primary breast cancer. However, HER2 discrepancies occur before and after surgery, creating difficulties in the administration of appropriate NAC. This study aimed to identify the clinical factors affecting these discrepancies. Read More

View Article and Full-Text PDF

Inhibiting of TACC3 Promotes Cell Proliferation, Cell Invasion and the EMT Pathway in Breast Cancer.

Front Genet 2021 3;12:640078. Epub 2021 Jun 3.

Biobank, Institute of Translational medicine, Shenzhen Second People's Hospital, Graduate School of Guangzhou Medical University, Shenzhen, China.

Accumulating evidences indicate that transforming acidic coiled-coil 3 (TACC3) is a tumor-related gene, was highly expressed in a variety of human cancers, which is involved in cancer development. However, the potential role of TACC3 in breast cancer remains largely unknown. In the present study, we found that TACC3 was highly-expressed in breast cancer tissues, and its level was positively correlated with the clinical features of breast cancer patients. Read More

View Article and Full-Text PDF

MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.

Curr Cancer Drug Targets 2021 Jun 18. Epub 2021 Jun 18.

The First Affiliated Hospital, Jinan University, Guangzhou 510632, China.

Background: The function of MALAT1, a kind of long non-coding RNAs (lncRNA), in HER2-positive breast cancer remains largely unexplored. Therefore, there is a need investigate the effect of MALAT1 on tumor development in HER2-positive breast cancer.

Objectives: We detected MALAT1 expression in HER2-positive breast cancer cells and tissues and analyzed the effects of MALAT1 on cell proliferation in HER2-positive breast cancer cell lines (BT-474 and SKBR3). Read More

View Article and Full-Text PDF

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.

Breast Cancer Res Treat 2021 Jun 20. Epub 2021 Jun 20.

Celltrion, Inc., Incheon, Republic of Korea.

Purpose: Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy and safety were comparable between treatments. We report updated safety and efficacy data after up to 3 years' follow-up. Read More

View Article and Full-Text PDF

Cancer stem cells in TNBC.

Semin Cancer Biol 2021 Jun 17. Epub 2021 Jun 17.

Research Center for Translational Medicine, Cancer Stem Cell Institute, East Hospital, Tongji University School of Medicine, Shanghai, 310000, People's Republic of China. Electronic address:

Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein. TNBC is considered to have poorer prognosis than other types of breast cancer because of a lack of effective therapeutic targets. The success of precision cancer therapies relies on the clarification of key molecular mechanisms that drive tumor growth and metastasis; however, TNBC is highly heterogeneous in terms of their cellular lineage composition and the molecular nature within each individual case. Read More

View Article and Full-Text PDF

Anticancer potential of novel α,β-unsaturated γ-lactam derivatives targeting the PI3K/AKT signaling pathway.

Biochem Pharmacol 2021 Jun 17:114659. Epub 2021 Jun 17.

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Arcavacata di Rende (CS), Italy. Electronic address:

Six recently synthesized alkyl (Z)-2-(2-oxopyrrolidin-3-ylidene)acetates were evaluated for their potential as cytotoxic and anticancer agents. All compounds were tested in the ERα positive MCF-7, triple negative MDA-MB-231, and Her2 SKBR-3 breast cancer cell lines. The most lipophilic derivatives, bearing the 4-isopropylphenyl (2) or 4-tert-butylphenyl (3) group at the γ-lactam nitrogen, proved to be cytotoxic against all the cancer cell lines tested (IC values ranging from 18 to 63 μM), exerting their greatest activity in SKBR-3 cells, with IC values of 33 and 18 μM, respectively. Read More

View Article and Full-Text PDF

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

Eur J Cancer 2021 Jun 16;152:223-232. Epub 2021 Jun 16.

Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000, Belgrade, Serbia. Electronic address:

Aim: The aim of the study was to assess patient preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in patients with HER2-positive early breast cancer in PHranceSCa (NCT03674112).

Materials And Methods: Patients who completed neoadjuvant P + H + chemotherapy + surgery were randomised 1:1 to three intravenous (IV) P + H cycles followed by three cycles of PH FDC SC or vice versa (crossover) and then chose subcutaneous (SC) injection or IV infusion to continue up to 18 cycles (continuation). Assessments were via patient and healthcare professional (HCP) questionnaires. Read More

View Article and Full-Text PDF

Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.

Int Immunopharmacol 2021 Jun 17;98:107876. Epub 2021 Jun 17.

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Sheffield, UK. Electronic address:

Breast cancer is the most common cancer type in women worldwide. Triple-negative breast cancer (TNBC), which is characterized by the absence of estrogen receptor/progesterone receptor (ER/PR) and human epidermal growth factor receptor 2 (Her2) expressions, has a poorer prognosis compared with non-TNBC breast tumors. Until recently systemic treatment for TNBC was confined to chemotherapy owing to the lack of actionable targets. Read More

View Article and Full-Text PDF

Labeling single domain antibody fragments with F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.

Nucl Med Biol 2021 Jun 11;100-101:24-35. Epub 2021 Jun 11.

Department of Radiology, Duke University Medical Center, Durham, NC, USA. Electronic address:

Introduction: Labeling single domain antibody fragments (sdAbs) with F is an attractive strategy for immunoPET. Earlier, we developed a residualizing label, N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([F]RL-I), synthesized via a click reaction for labeling sdAbs with F, that has attractive features but suffered from modest radiochemical yields and suboptimal hydrophobicity. Herein, we have evaluated the potential utility of an analogous agent, N-succinimidyl 3-(1-(2-(2-(2-(2-[F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate ([F]SFETGMB; [F]RL-III) designed to address these limitations. Read More

View Article and Full-Text PDF

Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.

Mol Oncol 2021 Jun 19. Epub 2021 Jun 19.

Department of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, 400016, China.

Estrogen-receptor-positive, and human epidermal growth factor receptor 2-negative (ER+HER2-) breast cancer accounts for ~60-70% of all cases of invasive breast carcinoma. High-grade ER+HER2- tumors respond poorly to endocrine therapy. In this study, we systematically analyzed clinical and multi-omics data to find potential strategies for personalized therapy of patients with high-grade ER+HER2- disease. Read More

View Article and Full-Text PDF

UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.

Cancer Chemother Pharmacol 2021 Jun 19. Epub 2021 Jun 19.

Department of Chemotherapy, Jiangsu Cancer Hospital, Nanjing, 210009, Jiangsu, China.

Purpose: This study aimed to investigate the possibility of UCP-2 inhibitor in reducing acquired resistance of trastuzumab to improve the outcome of patients receiving trastuzumab therapy by exploring the relationship between UCP-2 expression and HER2 signaling pathway and examining whether UCP-2 expression was modulated by trastuzumab treatment.

Methods: 32 women diagnosed with primary HER2-positive breast cancer were recruited in this study. Needle biopsy was obtained from patients before they received at least four cycles neoadjuvant therapy containing trastuzumab in combination with chemotherapy. Read More

View Article and Full-Text PDF

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy.

Cancer Rep (Hoboken) 2021 Jun 18:e1470. Epub 2021 Jun 18.

Department of Radiation Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have recently been approved for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer in association with endocrine therapy in postmenopausal women. Data on the interaction of CDK4/6 inhibition and radiotherapy are scarce, but some studies show unexpected toxicity.

Cases: We report three cases of unexpected severe or prolonged soft tissue, skin, and gastrointestinal toxicity in patients treated with a combination of radiotherapy and the CDK4/6 inhibitor palbociclib. Read More

View Article and Full-Text PDF

The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review.

Anticancer Drugs 2021 Jun 18. Epub 2021 Jun 18.

Department of Oncology and Hematology, people's Hospital of Leshan, Leshan, Sichuan.

Advanced breast cancer (ABC) is incurable. Previous studies have shown that vascular endothelial growth factor (VEGF) inhibitors play a significant role in the angiogenesis of breast carcinoma. Apatinib, a highly selective orally administered small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR2) has successfully been used as a second- and third-line agent in the management of ABC. Read More

View Article and Full-Text PDF

CD8 T cell immunity blocks the metastasis of carcinogen-exposed breast cancer.

Sci Adv 2021 Jun 18;7(25). Epub 2021 Jun 18.

Center for Cancer Immunology and Cutaneous Biology Research Center, Department of Dermatology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

The link between carcinogen exposure and cancer immunogenicity is unclear. Single exposure to 12-dimethylbenz[a]anthracene (DMBA) at puberty accelerated spontaneous breast carcinogenesis in mouse mammary tumor virus-polyoma middle tumor-antigen transgenic (MMTV-PyMT or PyMT) and MMTV-Her2/neu (Her2) mice. Paradoxically, DMBA-treated PyMT and Her2 animals were protected from metastasis. Read More

View Article and Full-Text PDF

[New therapeutic strategies in HER2-positive breast cancer].

Bull Cancer 2021 Jun 15. Epub 2021 Jun 15.

Centre Léon-Bérard, département de cancérologie médicale, 28, rue Laennec, 69008 Lyon, France. Electronic address:

Breast cancer with HER2-amplification accounts for 20% of breast cancers. The management of patients has dramatically changed with the advent of anti-HER2 treatment, especially the monoclonal antibodies since 2000 in the metastatic and (neo)-adjuvant setting, leading to an improvement of patient outcomes. If therapeutic arsenal has been gradually enhanced with the targeting of HER receptors family, resistances to these treatments are observed, hence the development of new therapeutic strategies. Read More

View Article and Full-Text PDF

[New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].

Bull Cancer 2021 Jun 15. Epub 2021 Jun 15.

Institut Curie, département d'oncologie médicale, 26, rue Ulm, 75005 Paris, France; Institut Curie, département de radio-pharmacologie, 35, rue Dailly, 92210 Saint-Cloud, France.

View Article and Full-Text PDF

Erratum to 'Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis': [ESMO Open Volume 6, Issue 2, April 2021, 100088].

ESMO Open 2021 Jun;6(3):100158

Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

View Article and Full-Text PDF